Naia Rare Diseases Inc to Present at 28th Annual ROTH Capital Conference on Tuesday, March 15, 2016
Richmond, CA–(Mar 11, 2016) – Naia Rare Diseases, Inc., a biotechnology company developing novel treatments for rare gastrointestinal diseases, today announced that it will be presenting at the 28th Annual ROTH Capital Conference on Tuesday, March 15, 2016. The Conference will be held at the Ritz Carlton in Dana Point, California.
The Company’s presentation by H. Daniel Perez, MD, Chief Executive Officer, is scheduled for March 15 at 4:00 p.m. PST, in the private company section. Dr. Perez will provide an update on the development of NB 1001, the Company’s novel drug candidate for the treatment of Short Bowel Syndrome (SBS), and the other programs in the Company’s pipeline.
Dr. Perez and Mark Bagnall, the Company’s Chief Financial Officer, will be available for meetings during the Conference.
About NB 1001
NB 1001 is a proprietary long-acting version of the GLP-1 agonist, exenatide, developed specifically to treat SBS. Unlike other GLP-1 agonists, NB 1001 will be dosed as a replacement therapy. Because of the lower overall exposure and favorable PK profile, NB 1001 will have a superior safety window, an important consideration in the care of SBS patients. NB 1001 works by slowing gastric contractions, increasing the transit time for food in the small bowel, and thus improving the absorption of nutrients. NB 1001 was previously developed to treat type 2 diabetes and in a 70 patient clinical study demonstrated efficacy with no observed side effects.
Naia Rare Diseases intends to file an IND for NB 1001 in the second quarter of 2016, and will conduct a Phase 1b open label, single dose, dose de-escalation study in adult SBS patients in the second half of 2016. The company believes that a single Phase 2/3 study will be required for product approval.
About Naia Rare Diseases
Naia Rare Diseases develops novel treatments for rare gastrointestinal diseases. The Company has programs focused on adult and pediatric SBS and other rare gastrointestinal disorders. Naia Rare Diseases is affiliated with Naia Pharmaceuticals which provides operating infrastructure and support in the development of new companies. For more information, please visit www.naiapharma.com.
Mark Bagnall, Naia Pharmaceuticals